InvestorsHub Logo

Sluicebox

08/18/21 5:49 PM

#351260 RE: sts66 #351242

PFE settled for 50% on sales in the Myovant deal in which they paid 600M upfront with an additional 3.6B in sales and regulatory milestones for Relugolix in prostate and two female deseases in US territory. And they split certain sales costs.